We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Suppressing Cancer Transcriptional Regulatory Complex Activity May Depend on Inositol Phosphate Signaling

By LabMedica International staff writers
Posted on 24 Jan 2012
A recent paper detailed the structure of a transcriptional regulatory complex, which revealed a link between inositol phosphate signaling and the regulation of histone deacetylase enzymes.

Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. More...
They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation.

Investigators at the University of Leicester (United Kingdom) described the structure of a complex between an HDAC and a corepressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor in the January 9, 2012, online edition of the journal Nature.

The structure revealed two remarkable features. First, the SMRT-DAD underwent a large structural rearrangement on forming the complex. Second, there was an essential inositol tetraphosphate molecule -- d-myo-inositol-(1,4,5,6)-tetrakisphosphate -- acting as an “intermolecular glue” between the two proteins.

Senior author Dr. John Schwabe, professor of biochemistry at the University of Leicester, said, “We have discovered a completely new and unexpected link between inositol phosphate signaling (in this case IP4) and the regulation of histone deacetylase enzymes, and hence transcriptional repression or gene silencing. In simple terms, we have shown that IP4 acts as a natural signaling molecule to regulate histone deacetylase enzymes, which play a key role in regulating gene expression. Apart from the considerable intellectual importance of understanding how transcription is regulated, repression complexes are important therapeutic targets for a number of cancers including several types of leukemia.”

“Our research identifies several new means to potentially target histone deacetylase enzymes therapeutically, either by using drugs to prevent IP4 binding to the enzyme or by interfering with the pathway through which the body makes IP4,” said Dr. Schwabe. “Thus, this work opens up a whole new area of research with potential for new drugs and a new approach to targeting histone deacetylase enzymes.”

Related Links:

University of Leicester





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Platelet Function Analyzer
AGGRENG-40
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.